The DOI matches its Crossref record; 17 of the 17 references it cites were found in a registry or an index.
The Senegalese government's highly active antiretroviral therapy initiative: an 18-month follow-up study
Abstract
OBJECTIVE: To study the feasibility, effectiveness, adherence, toxicity and viral resistance in an African government HAART initiative. METHODS: A prospective observational cohort study started in Dakar in August 1998. Initial treatment consisted of two nucleoside reverse transcriptase inhibitors and one protease inhibitor. The patients attended monthly medical examinations. Plasma HIV-1 RNA and CD4 cell counts were determined at baseline and every 6 months. Intention-to-treat analyses were performed. RESULTS: Fifty-eight treatment-naive patients, mostly infected by HIV-1 strain CRF02-AG, were enrolled. Most were at an advanced stage of HIV disease (86.2% had AIDS). Adherence was good in 87.9% of patients and treatment was effective in most of them. Thus, HIV-1 RNA was undetectable in 79.6, 71.2, 51.4 and 59.3% of patients at months 1, 6, 12 and 18, respectively and the median viral load reduction was approximately 2.5 log10 copies/ml. The CD4 cell count rose by a median of 82, 147 and 180 x 106 cells/l at months 6, 12 and 18, respectively. At the same time points, the cumulative probability of remaining alive or free of new AIDS-defining events was 94.8, 85.0 and 82.3%. Most adverse effects (80.8%) were mild or moderate and only two cases of drug resistance occurred. CONCLUSION: This study shows that HAART is feasible and well tolerated in African patients. Clinical and biological results were comparable to those seen in western cohorts, despite differences in the HIV-1 subtype distribution and an advanced disease stage when the treatment was initiated. Contrary to other recent studies in Africa, viral resistance rarely emerged.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Hammer, S. M., Squires, K. E., Hughes, M. D., Grimes, J. M., Demeter, L. M., Currier, J. S., Eron, J. J., Feinberg, J. E., Balfour, H. H., Deyton, L. R., et al. (1997) · New England Journal of Medicine · doi:10.1056/nejm199709113371101 · Cited by 2,640
Gulick, R. M., Mellors, J. W., Havlir, D., Eron, J. J., Gonzalez, C., McMahon, D., Richman, D. D., Valentine, F. T., Jonas, L., Meibohm, A., et al. (1997) · New England Journal of Medicine · doi:10.1056/nejm199709113371102 · Cited by 1,885
Adverse effects of antiretroviral therapy
Carr, A., & Cooper, D. A. (2000) · The Lancet · doi:10.1016/s0140-6736(00)02854-3 · Cited by 1,057
Ledergerber, B., Egger, M., Opravil, M., Telenti, A., Hirschel, B., Battegay, M., Vernazza, P., Sudre, P., Flepp, M., Furrer, H., et al. (1999) · The Lancet · doi:10.1016/s0140-6736(99)01122-8 · Cited by 906
Improved Survival Among HIV-Infected Individuals Following Initiation of Antiretroviral Therapy
Hogg, R. S. (1998) · JAMA · doi:10.1001/jama.279.6.450 · Cited by 850
French, M. A., Lenzo, N., John, M., Mallal, S. A., McKinnon, E. J., James, I. R., Price, P., Flexman, J. P., & Tay‐Kearney, M. (2000) · HIV Medicine · doi:10.1046/j.1468-1293.2000.00012.x · Cited by 413
Adherence to HIV combination therapy
Chesney, M. A., Morin, M., & Sherr, L. (2000) · Social Science & Medicine · doi:10.1016/s0277-9536(99)00468-2 · Cited by 341
Multilevel time series models with applications to repeated measures data
Goldstein, H., Healy, M. J. R., & Rasbash, J. (1994) · Statistics in Medicine · doi:10.1002/sim.4780131605 · Cited by 285
Preventing antiretroviral anarchy in sub-Saharan Africa
Harries, A., Nyangulu, D., Hargreaves, N., Kaluwa, O., & Salaniponi, F. (2001) · The Lancet · doi:10.1016/s0140-6736(01)05551-9 · Cited by 262
Vergne, L., Peeters, M., Mpoudi-Ngole, E., Bourgeois, A., Liegeois, F., Toure-Kane, C., Mboup, S., Mulanga-Kabeya, C., Saman, E., Jourdan, J., et al. (2000) · Journal of Clinical Microbiology · doi:10.1128/jcm.38.11.3919-3925.2000 · Cited by 185
Self-citation
Cited by
Adherence to Antiretroviral Therapy in Sub-Saharan Africa and North America: A Meta-analysis
Mills, E. J., Nachega, J. B., Buchan, I., Orbinski, J., Attaran, A., Singh, S., Rachlis, B., Wu, P., Cooper, C., Thabane, L., et al. (2006) · JAMA · doi:10.1001/jama.296.6.679 · Cited by 899
Outcomes after two years of providing antiretroviral treatment in Khayelitsha, South Africa
Coetzee, D., Hildebrand, K., Boulle, A., Maartens, G., Louis, F., Labatala, V., Reuter, H., Ntwana, N., & Goemaere, E. (2004) · AIDS · doi:10.1097/00002030-200404090-00006 · Cited by 584
Barriers to Antiretroviral Adherence for Patients Living with HIV Infection and AIDS in Botswana
Weiser, S., Wolfe, W., Bangsberg, D., Thior, I., Gilbert, P., Makhema, J., Kebaabetswe, P., Dickenson, D., Mompati, K., Essex, M., et al. (2003) · JAIDS Journal of Acquired Immune Deficiency Syndromes · doi:10.1097/00126334-200311010-00004 · Cited by 473
Ferradini, L., Jeannin, A., Pinoges, L., Izopet, J., Odhiambo, D., Mankhambo, L., Karungi, G., Szumilin, E., Balandine, S., Fedida, G., et al. (2006) · The Lancet · doi:10.1016/s0140-6736(06)68580-2 · Cited by 450
Barth, R. E., van der Loeff, M. F. S., Schuurman, R., Hoepelman, A. I., & Wensing, A. M. (2010) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(09)70328-7 · Cited by 310
Metadata
- Authors
- Laurent, C., Diakhaté, N., Fatou Ngom Gueye, N., Awa Touré, M., Salif Sow, P., Awa Faye, M., Gueye, M., Lanièce, I., Touré Kane, C., Liégeois, F., Vergne, L., Mboup, S., Badiane, S., Ndoye, I., & Delaporte, E.
- Venue
- AIDS
- Published
- 2002-07
- Volume
- 16
- Issue
- 10
- Pages
- 1363-1370
- ISSN
- 0269-9370 (ISSN-L)
- OpenAlex
- W2094514022
- Cited by
- 272
- References
- 17
- FWCI
- 17.20
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: The Senegalese government's highly active antiretroviral therapy initiative: an 18-month follow-up study. https://app.cochat.ai/papers/10.1097/00002030-200207050-00008
- The paper
- Laurent, C., Diakhaté, N., Fatou Ngom Gueye, N., Awa Touré, M., Salif Sow, P., Awa Faye, M., Gueye, M., Lanièce, I., Touré Kane, C., Liégeois, F., Vergne, L., Mboup, S., Badiane, S., Ndoye, I., & Delaporte, E. (2002). The Senegalese government's highly active antiretroviral therapy initiative: an 18-month follow-up study. AIDS. https://doi.org/10.1097/00002030-200207050-00008
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.